In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer

Tumor angiogenesis and lymphangiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer (NSCLC). Bevacizumab, which is a monoclonal antibody, was the initial inhibitor of angiogenesis and lymphangiogenesis that received approval for use in the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lung-Ching, Mokgautsi, Ntlotlang, Kuo, Yu-Cheng, Wu, Alexander T. H., Huang, Hsu-Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376976/
https://www.ncbi.nlm.nih.gov/pubmed/37509650
http://dx.doi.org/10.3390/biomedicines11072011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376976/
https://www.ncbi.nlm.nih.gov/pubmed/37509650
http://dx.doi.org/10.3390/biomedicines11072011

Ejemplares similares